P. Pockros

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2011 · 46 citations

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +11

An Open-label Pilot Trial of Cladibrine (2-Chlorodeoxyadenosine) in Patients with Primary Sclerosing Cholangitis

Andrea Duchini, Z.M. Younossi, Alan Saven et al. · Journal of Clinical Gastroenterology · 2000 · 38 citations

Medicine, Pharmacology, Pharmacotherapy +10

O168 THE FIRST PRIMARY BILIARY CIRRHOSIS (PBC) PHASE 3 TRIAL IN TWO DECADES – AN INTERNATIONAL STUDY OF THE FXR AGONIST OBETICHOLIC ACID IN PBC PATIENTS

Frederik Nevens, Pietro Andreoné, G. Mazzella et al. · Journal of Hepatology · 2014 · 31 citations

Medicine, Pharmacology, Pharmacotherapy +11

105 PHASE 2, MULTICENTER, RANDOMIZED STUDY OF AST-120 (SPHERICAL CARBON ADSORBENT) VS. LACTULOSE IN THE TREATMENT OF LOW-GRADE HEPATIC ENCEPHALOPATHY (HE)

P. Pockros, Tarek Hassanein, J Vierling et al. · Journal of Hepatology · 2009 · 25 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2012 · 24 citations

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +13